Thyroxine sulfate (T4 Sulfate)
(Synonyms: T4磺酸酯,T4 Sulfate) 目录号 : GC31328
硫酸甲状腺素 (T4 Sulfate) 是一种甲状腺激素代谢物。
Cas No.:77074-49-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Thyroxine sulfate is a thyroid hormone metabolite.
Thyroxine sulfate (T4S) is a normal component of human serum and amniotic fluid, and it is mostly derived from thyroxine peripherally and accumulates when type I 5-monodeiodinating activity is low in fetuses or inhibited by drugs, such as ipodate[1].
Significant amounts of thyroxine sulfate (T4S) in fetal sheep serum, meconium, bile, and amniotic and allantoic fluids are observed. T4S concentration in amniotic fluid from women at 18-19 weeks of gestation (25.5 ng/dL) is higher than that at 14-15 weeks of gestation (14.3 ng/dL). A significant rise in serum T4S is detected in hyperthyroid patients 1 day after ingestion of 1 g of ipodate[1]. Thyroxine undergoes significant sulfation in rats, and biliary excretion of T4S is enhanced if its type I deiodination is inhibited[2]. Serum T4S levels are clearly elevated compared with healthy references, and the decreased deiodination by liver D1 during critical illness appears to play a role in this increase in serum T4S levels[3].
[1]. Wu SY, et al. Identification of thyroxine-sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay. Thyroid. 1992 Summer;2(2):101-5. [2]. Rutgers M, et al. Effects of propylthiouracil on the biliary clearance of thyroxine (T4) in rats: decreased excretion of 3,5,3'-triiodothyronine glucuronide and increased excretion of 3,3',5'-triiodothyronine glucuronide and T4 sulfate. Endocrinology. 1989 Oct;125(4):2175-86. [3]. Peeters RP, et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type Ideiodinase activity. J Clin Endocrinol Metab. 2005 Dec;90(12):6460-5.
| Cas No. | 77074-49-8 | SDF | |
| 别名 | T4磺酸酯,T4 Sulfate | ||
| Canonical SMILES | N[C@@H](CC1=CC(I)=C(C(I)=C1)OC2=CC(I)=C(OS(=O)(O)=O)C(I)=C2)C(O)=O | ||
| 分子式 | C15H11I4NO7S | 分子量 | 856.93 |
| 溶解度 | DMSO : ≥ 31 mg/mL (36.18 mM) | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.167 mL | 5.8348 mL | 11.6696 mL |
| 5 mM | 0.2334 mL | 1.167 mL | 2.3339 mL |
| 10 mM | 0.1167 mL | 0.5835 mL | 1.167 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet